Literature review of international biosimilar medicines update – December 2016 to March 2017 | Australian Government Department of Health and Aged Care
Sandoz Biosimilar Technical Development Centre, Slovenia
Seminarul științific BIOSIM – DDS Diagnostic
Seminarul științific BIOSIM – DDS Diagnostic
Interchangeability of biosimilars in the EU – the industry impact
Samsung Biologics inks biosimilar manufacturing deal with Pfizer
MSD launches first Herceptin biosimilar in UK
Expert: generation of biobetters could push out biosimilar development
BioScript Solutions | What is a biosimilar?
Tocilizumab biosimilar successfully meets primary, secondary endpoints in Phase I study: Dr Reddy's Labs
Medicamente biosimilare, de ce are nevoie România să le adopte la scară largă | DCMedical.ro
Biosimilar Testing Services | Testing & Comparability
BioSim Research Group | Porto
Biosim - recenzii, fotografii, număr de telefon și adresă - Centre medicale din Târgu Mureș - Nicelocal.ro
Foundation hosts event to launch report on generic & biosimilar medicine manufacturers | Access to Medicine Foundation
US FDA accepts Biocon's cancer drug application for review - The Economic Times
Ogivri, trastuzumab biosimilar, eficient și sigur pentru tratamentul cancerului mamar și cancerului gastric HER2-pozitive
Zilele Spitalului Universitar de Urgenta Militar Central Dr. Carol Davila – Galerie multimedia
dr reddy: Dr Reddy's completes clinical studies of its proposed rituximab biosimilar candidate - The Economic Times
ADVANZ PHARMA enters into an exclusive agreement with Alvotech to commercialise a proposed biosimilar to Xolair® (omalizumab) | ADVANZ PHARMA
Română
Biosimilars as Partners in Oncology: Expert Guidance on Understanding and Incorporating Biosimilar Agents in Real-World Care
Switchback BioSim Innovations is excited to transition into our new space with expanded lab space, new project development labs, and a larger team! We... | By Switchback Medical | Facebook
Biosimilar Drug Master Class | McKesson
Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort - Gros - 2023 - United European Gastroenterology Journal - Wiley Online Library
Switchback BioSim Innovations is excited to transition into our new space with expanded lab space, new project development labs, and a larger team! We... | By Switchback Medical | Facebook
Amgen falls short in Epogen patent appeal but Pfizer stumble delays competition | Fierce Pharma
